natgillin/translations-raw huggingface dataset:
Therapeutic monitoring of valproate plasma levels did not indicate that valproate dosage adjustment is required after the introduction of concomitant olanzapine.
Terapevtsko spremljanje plazemskih koncentracij valproata ni pokazalo, da bi bila potrebna prilagoditev odmerka valproata po uvedbi so asnega zdravljenja z olanzapinom.
General CNS activity Caution should be exercised in patients who consume alcohol or receive medicinal products that can cause central nervous system depression.
Splošno delovanje na osrednje živ evje Pri bolnikih, ki uživajo alkohol ali prejemajo zdravila, ki lahko povzro ijo depresijo osrednjega živ evja, je potrebna previdnost.
The concomitant use of olanzapine with anti-Parkinsonian medicinal products in patients with Parkinson's disease and dementia is not recommended (see section 4.4).
So asna uporaba olanzapina z antiparkinsonskimi zdravili pri bolnikih s Parkinsonovo boleznijo in demenco ni priporo ena (glejte poglavje 4. 4).
QTc interval Caution should be used if olanzapine is being administered concomitantly with medicinal products known to increase QTc interval (see section 4.4).
QTc interval Potrebna je previdnost e dajemo olanzapin so asno z zdravili za katera je znano, da podaljšujejo QTc interval (glejte poglavje 4. 4).
There are no adequate and well-controlled studies in pregnant women.
Zadostnih in dobro kontroliranih študij pri nose nicah ni.
Patients should be advised to notify their physician if they become pregnant or intend to become pregnant during treatment with olanzapine.
Bolnicam je treba svetovati, da naj obvestijo svojega zdravnika, e zanosijo ali nameravajo zanositi med zdravljenjem z olanzapinom.
Nevertheless, because human experience is limited, olanzapine should be used in pregnancy only if the potential benefit justifies the potential risk to the foetus.
Ker pa so izkušnje pri loveku omejene, naj se olanzapin v nose nosti uporablja samo, e možna korist upravi i možno tveganje za plod.
Spontaneous reports have been very rarely received on tremor, hypertonia, lethargy and sleepiness, in infants born to mothers who had used olanzapine during the 3rd trimester.
Zelo redko so spontano poro ali o tresenju, hipertoniji, letargiji in zaspanosti pri dojen kih, rojenih materam, ki so uporabljale olanzapin v tretjem trimese ju.
In a study in breast-feeding, healthy women, olanzapine was excreted in breast milk.
V študiji pri doje ih zdravih ženskah se je olanzapin izlo al v materino mleko.
Patients should be advised not to breast-feed an infant if they are taking olanzapine.
Srednjo izpostavitev dojen ka (mg/ kg) v stanju dinami nega ravnovesja so ocenili na 1, 8% materinega odmerka olanzapina (mg/ kg). e jemljejo olanzapin, naj se bolnicam dojenje dojen ka odsvetuje.
Because olanzapine may cause somnolence and dizziness, patients should be cautioned about operating machinery, including motor vehicles.
Ker olanzapin lahko povzro i zaspanost in omoti nost, je treba bolnike opozoriti na previdnost glede upravljanja s stroji, vklju no z motornimi vozili.
Adults The most frequently (seen in 1% of patients) reported adverse reactions associated with the use of olanzapine in clinical trials were somnolence, weight gain, eosinophilia, elevated prolactin, cholesterol, glucose and triglyceride levels (see section 4.4), glucosuria, increased appetite, dizziness, akathisia, parkinsonism (see section 4.4), dyskinesia, orthostatic hypotension, anticholinergic effects,
Odrasli Najpogosteje poro ani (opažene pri ≥ 1% bolnikov) neželeni u inki, povezani z uporabo olanzapina v klini nih preskušanjih, so bili zaspanost, pove anje telesne mase, eozinofilija, zvišane ravni prolaktina, holesterola, glukoze in trigliceridov (glejte poglavje 4. 4), glikozurija, pove an apetit, omotica, akatizija, parkinsonizem (glejte poglavje 4. 4), diskinezija, ortostatska hipotenzija, antiholinergi ni u inki, prehodna asimptomatska zvišanja jetrnih transaminaz (glejte poglave 4. 4), izpuš aj, astenija, utrujenost in edem.
The following table lists the adverse reactions and laboratory investigations observed from spontaneous reporting and in clinical trials.
Naslednja tabela našteva neželene u inke in laboratorijske preiskave, ki so jih opazili iz spontanega poro anja in klini nih preskušanj.
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
V vsaki skupini pogostnosti so neželeni u inki navedeni po padajo i resnosti.
Very common (10%), common (1% and < 10%), uncommon (0.1% and < 1%), rare (0.01% and < 0.1%), very rare (< 0.01%), not known (cannot be estimated from the data available).
Našteti izrazi pogostnosti so definirani kot sledi: zelo pogosti (10%), pogosti (1% in < 10%), ob asni (0, 1% in < 1%), redki (0, 01% in < 0, 1%), zelo redki (< 0, 01%), ni znano (ocena ni možna iz danih podatkov).
Blood and the lymphatic system disorders
Bolezni krvi in limfati nega sistema
Immune system disorders Allergic reaction Metabolism and nutrition disorders Weight gain1
Bolezni imunskega sistema Alergijska reakcija Presnovne in prehranske motnje Pove
Elevated cholesterol levels2,3 Elevated glucose levels4 Elevated triglyceride levels2,5 Glucosuria Increased appetite
Zvišane ravni glukoze4 Zvišane ravni trigliceridov2, 5 Glikozurija Pove an apetit
Development or exacerbation of diabetes occasionally associated with ketoacidosis or coma, including some fatal cases (see section 4.4) Hypothermia
sladkorne bolezni, ob asno povezane s ketoacidozo ali komo, vklju no z nekaj smrtnimi primeri (glejte poglavje 4. 4) Hipotermija
Nervous system disorders Somnolence Cardiac disorders
Bolezni živ evja Zaspanost
Seizures where in most cases a history of seizures or risk factors for seizures were reported Neuroleptic malignant syndrome (see section 4.4) Dystonia (including oculogyration) Tardive dyskinesia Discontinuation symptoms7
Epilepti ni napadi, pri katerih so jih v ve ini primerov imeli že kdaj prej ali so poro ali o dejavnikih tveganja za epilepti ne napade Nevrolepti ni maligni sindrom (glejte poglavje 4. 4) Distonija (vklju no z okulogiracijo) Tardivne diskinezije Odtegnitveni simptomi7
Vascular disorders
8 Sr ne bolezni Žilne bolezni
Gastrointestinal disorders
Trombembolija (vklju no s plju no embolijo in globoko vensko trombozo)
Mild, transient anticholinergic effects including constipation and dry mouth
Blagi prehodni antiholinergi ni u inki, vklju no z zaprtjem in suhimi usti
8 Hepato-biliary disorders
Bolezni jeter, žol nika in žol evodov Bolezni kože in podkožja
Transient, asymptomatic elevations of hepatic transaminases (ALT, AST), especially in early treatment (see section 4.4)
Prehodna asimptomatska zvišanja jetrnih transaminaz (ALT, AST), posebno na za etku zdravljenja (glejte poglavje 4. 4)
Hepatitis (including hepatocellular, cholestatic or mixed liver injury)
Hepatitis (vklju no s hepatocelularno, holestatsko ali mešano okvaro jeter)
Rash
Izpuš aj
Musculoskeletal and connective tissue disorders Rhabdomyolysis Renal and urinary disorders Urinary hesitation Reproductive system and breast disorders Priapism General disorders and administration site conditions Asthenia Fatigue Oedema Investigations Elevated plasma prolactin levels8 1
Bolezni miši no- skeletnega sistema in vezivnega tkiva Rabdomioliza Bolezni se il Težave z za etkom mokrenja Motnje reprodukcije in dojk Priapizem Splošne težave in spremembe na mestu aplikacije Astenija Utrujenost Oteklina Preiskave Zvišane plazemske koncentracije prolaktina8 1
Clinically significant weight gain was observed across all baseline Body Mass Index (BMI) categories.
Klini no zna ilno zve anje telesne mase so opažali preko celotne osnove kategorij Indeksa telesne mase (BMI, Body Mass Index).
Weight gain 7% of baseline body weight was very common and 15% of baseline body weight was common.
Zve anje telesne mase za 7% od osnovne telesne mase je bilo zelo pogosto ter pogosto za 15%.
Patients gaining 25% of their baseline body weight with long-term exposure were very common.
Zve anje osnovne telesne mase za 25% se je pri dolgoro ni izpostavljenosti bolnikov pojavljalo zelo pogosto.
2 Mean increases in fasting lipid values (total cholesterol, LDL cholesterol, and triglycerides) were greater in patients without evidence of lipid dysregulation at baseline.
2 Povpre na povišanja vrednosti lipidov na teš e (celokupni holesterol, LDL holesterol in trigliceridi) so bila ve ja pri bolnikih brez o itne slabe regulacije lipidov na osnovi.
3 Observed for fasting normal levels at baseline (< 5.17 mmol/ l) which increased to high (6.2 mmol/ l).
9 3 Opazovano pri osnovnih normalnih ravneh na teš e (< 5, 17 mmol/ l), ki so se povišale na visoke (6, 2 mmol/ l).
Changes in total fasting cholesterol levels from borderline at baseline (5.17- < 6.2 mmol/ l) to high (6.2 mmol/ l) were very common.
Zelo pogoste so bile spremembe v ravneh celokupnega holesterola na teš e z mejnih osnovnih vrednosti (5, 17 mmol/ l - < 6, 2 mmol/ l) na visoke (6, 2 mmol/ l).
4 Observed for fasting normal levels at baseline (< 5.56 mmol/ l) which increased to high (7 mmol/ l).
4 Opazovano pri osnovnih normalnih ravneh na teš e (< 5, 56 mmol/ l), ki so se povišale na visoke (7 mmol/ l).
Changes in fasting glucose from borderline at baseline (5.56 - < 7 mmol/ l) to high (7 mmol/ l) were very common.
Zelo pogoste so bile spremembe v ravneh glukoze na teš e z mejnih osnovnih vrednosti (5, 56 mmol/ l - < 7 mmol/ l) na visoke (7 mmol/ l).
5 Observed for fasting normal levels at baseline (< 1.69 mmol/ l) which increased to high (2.26 mmol/ l).
5 Opazovano pri osnovnih normalnih ravneh na teš e (< 1, 69 mmol/ l), ki so se povišale na visoke (2, 26 mmol/ l).
Changes in fasting triglycerides from borderline at baseline (1.69 mmol/ l - < 2.26 mmol/ l) to high (2.26 mmol/ l) were very common.
Zelo pogoste so bile spremembe v ravneh trigliceridov na teš e z mejnih osnovnih vrednosti (1, 69 mmol/ l - < 2, 26 mmol/ l) na visoke (2, 26 mmol/ l).
6 In clinical trials, the incidence of parkinsonism and dystonia in olanzapine-treated patients was numerically higher, but not statistically significantly different from placebo.
6 V klini nih preskušanjih je bila incidenca parkinsonizma in distonije pri bolnikih, zdravljenih z olanzapinom, števil no ve ja, a se ni statisti no zna ilno razlikovala od placeba.
In the absence of detailed information on the pre-existing history of individual acute and tardive extrapyramidal movement disorders, it can not be concluded at present that olanzapine produces less tardive dyskinesia and/ or other tardive extrapyramidal syndromes.
Zaradi pomanjkanja podrobnih anamnesti nih podatkov o preteklih posameznih akutnih in poznih ekstrapiramidnih motnjah gibanja trenutno ni možno zaklju iti, da olanzapin povzro a manj tardivnih diskinezij in/ ali drugih zapoznelih ekstrapiramidnih sindromov.
9 7 Acute symptoms such as sweating, insomnia, tremor, anxiety, nausea and vomiting have been reported when olanzapine is stopped abruptly.
7 Pri nenadni prekinitvi zdravljenja z olanzapinom so poro ali o akutnih simptomih kot so znojenje, nespe nost, tresenje, tesnoba, slabost in bruhanje.
8 Associated clinical manifestations (e. g., gynaecomastia, galactorrhoea, and breast enlargement) were rare.
8 Redka so bila povezana klini na izražanja (npr. ginekomastija, galaktoreja in pove anje prsi).
In most patients, levels returned to normal ranges without cessation of treatment.
Pri ve ini bolnikov so se ravni vrnile v normalne meje brez ukinitve zdravljenja.
Long-term exposure (at least 48 weeks) The proportion of patients who had adverse, clinically significant changes in weight gain, glucose, total/ LDL/ HDL cholesterol or triglycerides increased over time.
Dolgoro na izpostavljenost (najmanj 48 tednov) Delež bolnikov, ki so imeli neželene, klini no zna ilne spremembe telesne mase, glukoze, celokupnega/ LDL/ HDL holesterola ali trigliceridov se je s asom pove al.
In adult patients who completed 9-12 months of therapy, the rate of increase in mean blood glucose slowed after approximately 4-6 months.
Pri odraslih bolnikih, ki so zaklju ili 9- 12 mesecev terapije, se je razmerje zvišanja povpre ne glukoze v krvi upo asnilo po približno 4- 6 mesecih.
Additional information on special populations In clinical trials in elderly patients with dementia, olanzapine treatment was associated with a higher incidence of death and cerebrovascular adverse reactions compared to placebo (see section 4.4).
Dodatne informacije glede posebnih skupin bolnikov V klini nih preskušanjih pri starejših bolnikih z demenco je bilo zdravljenje z olanzapinom povezano z višjo incidenco smrti in cerebrovaskularnih neželenih reakcij v primerjavi s placebom (glejte poglavje 4. 4).
Very common adverse reactions associated with the use of olanzapine in this patient group were abnormal gait and falls.
Zelo pogosta neželena u inka povezana z uporabo olanzapina v tej skupini bolnikov sta bila neobi ajna hoja in padci.
Pneumonia, increased body temperature, lethargy, erythema, visual hallucinations and urinary incontinence were observed commonly.
Pogosto so opažali plju nico, povišano telesno temperaturo, letargijo, eritem, vidne halucinacije ter inkontinenco urina.
In clinical trials in patients with drug-induced (dopamine agonist) psychosis associated with Parkinson’ s disease, worsening of Parkinsonian symptomatology and hallucinations were reported very commonly and more frequently than with placebo.
V klini nih preskušanjih pri bolnikih s psihozami povzro enimi z zdravili (dopaminski agonisti) povezanimi s Parkinsonovo boleznijo, so pogosto ter pogosteje kot pri placebu poro ali o poslabšanju simptomatologije Parkinsonove bolezni in halucinacijah.
In one clinical trial in patients with bipolar mania, valproate combination therapy with olanzapine resulted in an incidence of neutropenia of 4.1%; a potential contributing factor could be high plasma valproate levels.
V enem klini nem preskušanju pri bolnikih z bipolarno manijo, je kombinirano zdravljenje z valproatom in olanzapinom povzro ilo incidenco nevtropenije 4, 1%; možen vzro ni dejavnik so lahko visoke plazemske ravni valproata.
Olanzapine administered with lithium or valproate resulted in increased levels (≥ 10%) of tremor, dry mouth, increased appetite, and weight gain.
Olanzapin dan z litijem ali valproatom je povzro il zvišane ravni (10%) tresenja, suhih ust, pove anega apetita in pove anja telesne mase.
Speech disorder was also reported commonly.
Pogosto so poro ali tudi o motnji govora.
During treatment with olanzapine in combination with lithium or divalproex, an increase of ≥ 7% from baseline body weight occurred in 17.4% of patients during acute treatment (up to 6 weeks).
Med zdravljenjem z olanzapinom v kombinaciji z litijem ali divalproeksom se je pri 17, 4% bolnikov med akutnim zdravljenjem (do 6 tednov) pojavilo pove anje telesne mase za > 7% od osnovne.
Long-term olanzapine treatment (up to 12 months) for recurrence prevention in patients with bipolar disorder was associated with an increase of ≥ 7% from baseline body weight in 39.9% of patients.
Dolgoro no zdravljenje z olanzapinom (do 12 mesecev) za prepre evanje ponovnega pojava bolezni pri bolnikih z bipolarno motnjo je bilo povezano s pove anjem telesne mase za 7% z osnove pri 39, 9% bolnikov.
Although no clinical studies designed to compare adolescents to adults have been conducted, data from the adolescent trials were compared to those of the adult trials.
Otroci in mladostniki Olanzapin ni indiciran za zdravljenje otrok in mladostnikov mlajših od 18 let. eprav niso opravili klini nih študij z namenom primerjave mladostnikov z odraslimi, so podatke iz preskušanj pri mladostnikih primerjali s tistimi iz preskušanj pri odraslih.
The following table summarises the adverse reactions reported with a greater frequency in adolescent patients (aged 13-17 years) than in adult patients or adverse reactions only identified during short- term clinical trials in adolescent patients.
10 Naslednja tabela vklju uje neželene u inke, ki so jih poro ali z višjo pogostnostjo pri mladostnikih (starih 13- 17 let) kot pri odraslih bolnikih ali neželene u inke, ki so jih ugotovili samo v kratkoro nih klini nih preskušanjih pri mladostnikih.
Clinically significant weight gain (7%) appears to occur more frequently in the adolescent population compared to adults with comparable exposures.
Videti je, da se klini no zna ilno zve anje telesne mase (7%) pojavlja pogosteje pri populaciji mladostnikov v primerjavi z odraslimi pri primerljivi izpostavljenosti.
The magnitude of weight gain and the proportion of adolescent patients who had clinically significant weight gain were greater with long-term exposure (at least 24 weeks) than with short-term exposure.
Obseg pove anja telesne mase ter razmerje mladostnikov, ki so imeli klini no zna ilno zve anje telesne mase, sta bila višja pri dolgoro ni izpostavljenosti (najmanj 24 tednov) kot pri kratkoro ni izpostavljenosti.
Very common (10%), common (1% and < 10%).
Našteti izrazi pogostnosti so definirani kot sledi: zelo pogosti (10%), pogosti (1% in < 10%).
10 Metabolism and nutrition disorders Very common:
Presnovne in prehranske motnje Zelo pogosti:
Common:
Pove anje telesne mase9, zvišane ravni trigliceridov10, pove an apetit Pogosti:
Elevated cholesterol levels11 Nervous system disorders Very common:
Zvišane ravni holesterola11 Bolezni živ evja Zelo pogosti:
Sedation (including: hypersomnia, lethargy, somnolence).
Sedacija (vklju no s: hipersomnijo, letargijo, zaspanostjo) Bolezni prebavil Pogosti:
Dry mouth Hepato-biliary disorders Very common:
Suha usta Bolezni jeter, žol nika in žol evodov Zelo pogosti:
9 Weight gain 7% of baseline body weight (kg) was very common and 15% of baseline body weight was common.
Nizek celokupni bilirubin, visok GGT, zvišane plazemske koncentracije prolaktina12 9 Pove anje telesne mase za 7% od osnovne telesne mase (kg) je bilo zelo pogosto ter pogosto za 15%.
With long-term exposure (at least 24 weeks), approximately half of adolescent patients gained 15% and almost a third gained 25% of their baseline body weight.
Pri dolgoro ni izpostavljenosti (najmanj 24 tednov) je približno polovica mladostnikov pridobila 15% in skoraj tretjina 25% od njihove osnovne telesne mase.
Among adolescent patients, mean weight gain was greatest in patients who were overweight or obese at baseline.
Med mladostniki je bilo povpre no pove anje ve je pri bolnikih, ki so bili v osnovi pretežki ali debeli.
10 Observed for fasting normal levels at baseline (< 1.016 mmol/ l) which increased to high (1.467 mmol/ l) and changes in fasting triglycerides from borderline at baseline (1.016 mmol/ l - < 1.467 mmol/ l) to high (1.467 mmol/ l).
10 Opazovano pri osnovnih normalnih ravneh na teš e (< 1, 016 mmol/ l), ki so se povišale na visoke (1, 467 mmol/ l) in spremembe v ravneh trigliceridov na teš e z mejnih osnovnih vrednosti (1, 016 mmol/ l - < 1, 467 mmol/ l) na visoke (1, 467 mmol/ l).
11 Changes in total fasting cholesterol levels from normal at baseline (< 4.39 mmol/ l) to high (5.17 mmol/ l) were observed commonly.
11 Pogosto so opazovali spremembe v ravneh celokupnega holesterola na teš e z normalnih osnovnih vrednosti (< 4, 39 mmol/ l), ki so se povišale na visoke (5, 17 mmol/ l).
Changes in total fasting cholesterol levels from borderline at baseline (4.39 - < 5.17 mmol/ l) to high (5.17 mmol/ l) were very common.
Zelo pogoste so bile spremembe v ravneh celokupnega holesterola na teš e z mejnih osnovnih vrednosti (4, 39 mmol/ l - < 5, 17 mmol/ l) na visoke (5, 17 mmol/ l).
12 Elevated plasma prolactin levels were reported in 47.4% of adolescent patients.
12 O zvišanih plazemskih koncentracijah prolaktina so poro ali pri 47, 4% mladostnikov.
Signs and symptoms Very common symptoms in overdose (> 10% incidence) include tachycardia, agitation/ aggressiveness, dysarthria, various extrapyramidal symptoms, and reduced level of consciousness ranging from sedation to coma.
Znaki in simptomi Zelo pogosti simptomi pri prevelikem odmerjanju (incidenca > 10%) vklju ujejo tahikardijo, vznemirjenost/ nasilnost, dizartrijo, razli ne ekstrapiramidne simptome in motnje zavesti v razponu od sedacije do kome.
Other medically significant sequelae of overdose include delirium, convulsion, coma, possible neuroleptic malignant syndrome, respiratory depression, aspiration, hypertension or hypotension, cardiac arrhythmias (< 2% of overdose cases) and cardiopulmonary arrest.
Druge zdravstveno pomembne posledice prevelikega odmerjanja vklju ujejo delirij, konvulzije, komo, možen nevrolepti ni maligni sindrom, depresijo dihanja, aspiracijo, hipertenzijo ali hipotenzijo, motnje sr nega ritma (< 2% primerov prevelikega odmerjanja) in kardiopulmonalni zastoj.
Fatal outcomes have been reported for acute overdoses as low as 450 mg but survival has also been reported following acute overdose of 1,500 mg.
Poro ali so o smrtnih izidih pri akutnih prevelikih odmerjanjih tako nizkih odmerkov, kot je 450 mg, vendar so poro ali tudi o preživetju po akutnem prevelikem odmerjanju z odmerkom 1500 mg.
Management of overdose There is no specific antidote for olanzapine.
11 Ravnanje v primeru prevelikega odmerjanja Za olanzapin ni specifi nega antidota.
Induction of emesis is not recommended.
Sproženje bruhanja ni priporo eno.
The concomitant administration of activated charcoal was shown to reduce the oral bioavailability of olanzapine by 50 to 60%.
Izkazalo se je, da se ob so asnem jemanju aktivnega oglja peroralna biološka uporabnost olanzapina zmanjša za 50 do 60%.
Symptomatic treatment and monitoring of vital organ function should be instituted according to clinical presentation, including treatment of hypotension and circulatory collapse and support of respiratory function.
Glede na klini no sliko je treba uvesti simptomatsko zdravljenje in spremljanje delovanja vitalnih organov, vklju no z zdravljenjem hipotenzije in cirkulatorne odpovedi ter podporo dihanja.
Do not use epinephrine, dopamine, or other sympathomimetic agents with beta- agonist activity since beta stimulation may worsen hypotension.
Ne uporabljajte adrenalina, dopamina ali drugih simpatikomimetikov z beta- agonisti nim delovanjem, ker lahko beta stimulacija poslabša hipotenzijo.
In preclinical studies, olanzapine exhibited a range of receptor affinities (Ki; < 100 nM) for serotonin 5HT2A/ 2C, 5HT3, 5HT6; dopamine D1, D2, D3, D4, D5; cholinergic muscarinic receptors m1-m5; α 1 adrenergic; and histamine H1 receptors.
V predklini nih študijah je olanzapin pokazal razpon afinitet do receptorjev (Ki; < 100 nM) za serotonin 5- HT2A/ 2C, 5- HT3, 5- HT6; dopamin D1, D2, D3, D4, D5; holinergi nih muskarinskih receptorjev m1- m5; adrenergi nih α1; in histaminskih H1 receptorjev.
Animal behavioral studies with olanzapine indicated 5HT, dopamine, and cholinergic antagonism, consistent with the receptor-binding profile.
Vedenjske študije z olanzapinom na živalih so kazale na 5HT, dopaminski in holinergi ni antagonizem v skladu s profilom vezave na receptorje.
Olanzapine demonstrated a greater in vitro affinity for serotonin 5HT2 than dopamine D2 receptors and greater 5HT2 than D2 activity in vivo, models.
V pogojih in vitro je olanzapin pokazal ve jo afiniteto za serotoninske 5- HT2 kot za dopaminske D2 receptorje in ve jo 5- HT2 kot D2 aktivnost v modelih in vivo.
Electrophysiological studies demonstrated that olanzapine selectively reduced the firing of mesolimbic (A10) dopaminergic neurons, while having little effect on the striatal (A9) pathways involved in motor function.
Elektrofiziološke študije so pokazale, da je olanzapin selektivno zmanjšal proženje mezolimbi nih (A10) dopaminergi nih nevronov, medtem ko je imel majhen u inek na striatne (A9) poti, vpletene v motori no delovanje.
Olanzapine reduced a conditioned avoidance response, a test indicative of antipsychotic activity, at doses below those producing catalepsy, an effect indicative of motor side-effects.
Olanzapin je zmanjšal pogojeni umaknitveni odziv, test, ki kaže na antipsihoti no delovanje, pri odmerkih, nižjih od tistih, ki povzro ijo katalepsijo, u inek, ki kaže na motori ne neželene u inke.
Unlike some other antipsychotic agents, olanzapine increases responding in an “ anxiolytic” test.
Za razliko od nekaterih drugih antipsihotikov olanzapin pove a odzivanje v » anksioliti nem « testu.